Coadministration of AZD0530 and Gefitinib increases growth inhibition in vitro « Kinase News

Blogroll
Tags
AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

Coadministration of AZD0530 and Gefitinib increases growth inhibition in vitro

Posted on July 2, 2008 by crimsoncanary

In vitro studies with Src inhibitor AZD0530 and EGFR kinase inhibitor Geftinib show that treatment with both drugs resulted in greater inhibition of head and neck squamous cell carcinoma cell growth and invasion compared with either agent alone.

Filed under: kinase | Tagged: AstraZeneca, AZD-0530, AZD0530, EGF kinase, EGFR, gefitinib, Iressa, kinase, Preclinical, Research, SRC

« Kissei publish data on new pyrimidine Syk inhibitors Coadministration of CDK inhibitor seliciclib with EGFR inhibitors increases activity »